Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28228647 | 0.69 | RAPGEF4 (0.39) | MEN1LMNAKMT2ARAPGEF4 | |
| SCHEMBL10994353 | 0.69 | RAPGEF4 (0.43) | MEN1LMNAKMT2ASMN1; SMN2RAPGEF4 | |
| SCHEMBL812665 | 0.68 | TSHR (0.41) | — | |
| SCHEMBL10063564 | 0.67 | RAPGEF4 (0.33) | RAPGEF4 | |
| SCHEMBL295495 | 0.65 | ACHE (0.35) | MEN1LMNAKMT2A | |
| SCHEMBL17943451 | 0.64 | RAPGEF4 (0.35) | LMNASMN1; SMN2RAPGEF4 | |
| SCHEMBL2360359 | 0.62 | CRHR1 (0.46) | HPGDMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL1367414 | 0.62 | CRHR1 (0.42) | HPGDMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL15420053 | 0.62 | RIPK1 (0.33) | MEN1KMT2A | |
| SCHEMBL13550107 | 0.62 | RAPGEF4 (0.40) | MEN1LMNAKMT2ASMN1; SMN2RAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063205-B2 | Method for producing 2-oxazoline analogue or 1,3-oxazine analogue | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2011-11-22 | — | — | US | disclosed |
| US-20090281309-A1 | METHOD FOR PRODUCING 2-OXAZOLINE ANALOGUE OR 1,3-OXAZINE ANALOGUE | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1956012-A1 | METHOD FOR PRODUCING 2-OXAZOLINE ANALOGUE OR 1,3-OXAZINE ANALOGUE | National University Corporation Hokkaido University (JP) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281309-A1 | METHOD FOR PRODUCING 2-OXAZOLINE ANALOGUE OR 1,3-OXAZINE ANALOGUE | OXA1L, SULT1A1, DAO | HPGD 2260/4885MEN1 4342/4885LMNA 4507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.